Skip to main content

Table 1 Comparison of clinical data between the two groups

From: Correlation between galectin-3, RDW, Hepc, HS and ferritin and prognosis of patients with acute onset of chronic heart failure

Variables

The effective group (n = 66)

The non-effective group (n = 26)

χ2

P

Sex (male/female) (n)

31/35

14/12

0.353

0.552

Age (years)

59.28 ± 10.65

59.67 ± 10.42

− 0.159

0.874

BMI (kg/m2)

23.43 ± 4.48

23.13 ± 4.93

0.375

0.709

NYHA cardiac function class (%)

 II

17 (25.76%)

6 (23.08%)

0.132

0.936

 III

19 (28.79%)

7 (26.92%)

  

 IV

30 (45.46%)

13 (50.00%)

  

Comorbidities (%)

 Obesity

6 (9.09%)

4 (15.38%)

0.763

0.383

 COPD history

7 (10.61%)

2 (7.69%)

0.179

0.672

 Hyperlipidemia

11 (16.67%)

9 (34.62%)

3.532

0.060

 Diabetes

14 (21.21%)

5 (19.23%)

0.045

0.833

 Hypertension

3(4.55%)

8 (30.77%)

12.185

< 0.001

Drinking (n)

12 (18.19%)

5 (19.23%)

0.014

0.907

Smoking (n)

15 (22.73%)

7 (26.92%)

0.180

0.671

CHD (n)

3 (4.55%)

13 (50%)

26.824

< 0.001

Atrial fibrillation (n)

4 (6.06%)

2 (7.69%)

0.081

0.775

Cerebrovascular disease (n)

9 (13.64%)

4 (15.38%)

0.047

0.828

Valvular heart disease (n)

3 (4.55%)

14 (53.85%)

8.169

0.004

Routine inspection indicators

 BNP before treatment (ng/L)

441.29 ± 78.93

440.78 ± 79.38

0.028

0.978

 BNP after treatment (ng/L)

303.29 ± 71.29

337.92 ± 76.28

− 1.701

0.092

 NT-pro-BNP before treatment (ng/L)

1461.89 ± 432.09

1459.87 ± 442.97

0.021

0.984

 NT-pro-BNP after treatment (ng/L)

518.75 ± 127.98

571.76 ± 136.93

− 1.754

0.083

 CTn-I before treatment (ng/L)

245.98 ± 47.98

253.09 ± 49.82

− 0.633

0.528

 CTn-I after treatment (ng/L)

193.98 ± 43.29

207.92 ± 47.93

− 1.349

0.181

 Serum iron (pg/dI)

19.08 ± 3.29

18.28 ± 3.28

1.051

0.296

 Serum sodium (mmol/L)

134.78 ± 30.92

133.87 ± 32.56

0.125

0.903

 Serum potassium (mmol/L)

4.21 ± 0.76

4.19 ± 0.72

0.115

0.909

 Blood glucose (mmol/L)

5.01 ± 1.05

5.13 ± 1.09

− 0.488

0.627

 Glycated hemoglobin (%)

5.37 ± 1.02

5.43 ± 1.05

− 0.207

0.837

 Blood urea nitrogen (mmol/L)

6.03 ± 1.73

5.89 ± 1.83

0.335

0.739

 Serum creatinine (μmol/L)

93.29 ± 17.28

91.38 ± 16.53

0.493

0.624

 eGFR (mL/min/1.73 m2)

76.93 ± 12.38

74.73 ± 13.29

0.752

0.454

Echocardiography before treatment

 LVEDd (mm)

68.73 ± 7.09

69.21 ± 7.46

− 0.288

0.774

 LVIDs (mm)

43.87 ± 6.87

44.91 ± 6.54

− 0.662

0.502

 LVEF (%)

35.58 ± 5.91

34.98 ± 5.03

0.456

0.649

 LVPWT (mm)

14.23 ± 3.11

14.45 ± 3.18

− 0.304

0.762

 LVST (mm)

14.87 ± 3.21

14.94 ± 3.42

− 0.092

0.927

 RA (mm)

62.19 ± 12.87

62.79 ± 13.17

− 0.198

0.842

 RVD (mm)

21.76 ± 4.98

21.85 ± 5.65

− 0.075

0.944

Echocardiography after treatment

 LVIDd

49.87 ± 13.26

50.32 ± 13.18

− 0.147

0.883

 LVIDs (mm)

39.65 ± 6.59

40.98 ± 6.75

− 0.866

0.389

 LVEF (%)

47.93 ± 5.37

46.09 ± 5.48

1.404

0.640

 LVPWT (mm)

10.37 ± 2.78

11.09 ± 2.87

− 1.108

0.271

 LVST (mm)

10.32 ± 3.01

10.89 ± 2.98

− 0.819

0.414

 RA (mm)

49.38 ± 10.28

50.38 ± 10.03

− 0.423

0.673

 RVD (mm)

16.03 ± 3.45

16.34 ± 3.56

− 0.385

0.701

  1. NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; BNP, B-type natriuretic peptide; NT-pro-BNP, N-terminal pro-BNP; cTn, cardiac troponin; eGFR, estimated glomerular filtration rate; LVEDd, left ventricular end-diastolic diameter; LVIDs, left ventricular internal dimension systole; LVEF, left ventricular ejection fraction; LVPWT, left ventricular posterior wall thickness; LVST, left ventricular septal thickness; RA, right atrium; RVD, right ventricle diameter
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us